American drug-maker Pfizer said Friday it has requested emergency use authorization from the U.S. Food and Drug Administration (or FDA) for its COVID-19 vaccine. Pfizer and its German partner BioNTech noted they have also started a similar process with regulatory agencies in Europe. They are also doing so in other countries, including Japan, Canada and Australia. The action came just two days after the drug-makers announced final results of their large vaccine study. Dr. Albert Bourla is Pfizer Chairman and chief executive. He said in a statement, “Our work to deliver a safe and effective vaccine has never been more urgent.” He noted that the company is looking “to secure authorization of our vaccine candidate as quickly as possible.”